Signaturefd LLC Acquires 7,077 Shares of Haleon plc (NYSE:HLN)

Signaturefd LLC raised its stake in Haleon plc (NYSE:HLN) by 6.5% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 116,455 shares of the company’s stock after acquiring an additional 7,077 shares during the period. Signaturefd LLC’s holdings in Haleon were worth $962,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Hexagon Capital Partners LLC grew its stake in shares of Haleon by 107.3% during the fourth quarter. Hexagon Capital Partners LLC now owns 4,236 shares of the company’s stock valued at $35,000 after buying an additional 2,193 shares during the last quarter. Cultivar Capital Inc. acquired a new position in Haleon during the 2nd quarter valued at approximately $40,000. Allspring Global Investments Holdings LLC acquired a new stake in Haleon during the 1st quarter worth about $43,000. Tower Research Capital LLC TRC boosted its position in Haleon by 146.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,398 shares of the company’s stock valued at $44,000 after buying an additional 3,211 shares during the last quarter. Finally, SRS Capital Advisors Inc. increased its stake in shares of Haleon by 456.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 5,458 shares of the company’s stock worth $45,000 after acquiring an additional 4,477 shares during the period. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Berenberg Bank initiated coverage on shares of Haleon in a research report on Tuesday, August 6th. They set a “buy” rating for the company. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy”.

Haleon Stock Up 0.9 %

NYSE HLN traded up $0.09 on Friday, hitting $10.18. 3,156,245 shares of the stock were exchanged, compared to its average volume of 5,052,229. Haleon plc has a fifty-two week low of $7.70 and a fifty-two week high of $10.23. The company has a 50-day moving average price of $9.20 and a 200-day moving average price of $8.65. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. The company has a market cap of $46.48 billion, a PE ratio of 33.93, a PEG ratio of 2.69 and a beta of 0.24.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The business had revenue of $3.50 billion during the quarter, compared to analyst estimates of $3.55 billion. Haleon had a net margin of 9.71% and a return on equity of 19.85%. During the same period last year, the company earned $0.08 earnings per share. Sell-side analysts anticipate that Haleon plc will post 0.47 EPS for the current fiscal year.

Haleon Cuts Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Thursday, September 19th. Shareholders of record on Friday, August 16th will be issued a dividend of $0.0514 per share. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, August 16th. Haleon’s payout ratio is 33.33%.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.